Synapsoft logo
AI Insights from Disclosures
Searching...
MedPacto, Inc. 235980
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
MedPacto, Inc. was formed in 2013 when its new drug research institute separated from and became independent of TheragenEtex, a KOSDAQ-listed company that pursues precision medicine and new drug development based on state-of-the-art genome decoding technology and bioinformatics. Based on the genome-based cancer research achievements of CEO Kim Sung-jin, the company aims to develop innovative new drugs for the treatment of intractable cancers through the discovery of new anti-cancer targets and biomarkers.
Representative Director U Jeongwon
Founded June 19, 2013
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 13581-0232363
Business number 135-86-33854
Phone Number 02-6938-0200
Fax Number 02-6938-0280
Company Address 92 Myeongdal-ro, Seocho-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant